Appendix I: Explanation of guidelines and evidence levels

Clinical guidelines are: 'systematically developed statements which assist clinicians and patients in making decisions about appropriate treatment for specific conditions'. Each guideline is systematically developed using a standardised methodology. Exact details of this process can be found in Clinical Governance Advice No.1 *Development of RCOG Green-top Guidelines* (available on the RCOG website at http://www.rcog.org.uk/green-top-development). These recommendations are not intended to dictate an exclusive course of management or treatment. They must be evaluated with reference to individual patient needs, resources and limitations unique to the institution and variations in local populations. It is hoped that this process of local ownership will help to incorporate these guidelines into routine practice. Attention is drawn to areas of clinical uncertainty where further research may be indicated.

The evidence used in this guideline was graded using the scheme below and the recommendations formulated in a similar fashion with a standardised grading scheme.

Classification of evidence levels

1++	High-quality meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a low risk of bias
1–	Meta-analyses, systematic reviews of randomised controlled trials or randomised controlled trials with a high risk of bias
2++	High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with a very low risk of confounding, bias or chance and a high probability that the relationship is causal
2+	Well-conducted case–control or cohort studies with a low risk of confounding, bias or chance and a moderate probability that the relationship is causal
2–	Case–control or cohort studies with a high risk of confounding, bias or chance and a significant risk that the relationship is not causal
3	Non-analytical studies, e.g. case reports, case series
4	Expert opinion

Grades of recommendations

A	At least one meta-analysis, systematic reviews or RCT rated as 1++, and directly applicable to the target population; or A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population and demonstrating overall consistency of results
B	A body of evidence including studies rated as 2++ directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 1++ or 1+
C	A body of evidence including studies rated as 2+ directly applicable to the target population, and demonstrating overall consistency of results; or Extrapolated evidence from studies rated as 2++
D	Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+

Good practice point

✓	Recommended best practice based on the clinical experience of the guideline development group

This guideline was produced on behalf of the Guidelines Committee of the Royal College of Obstetricians and Gynaecologists by:

Mr LWM Impey FRCOG, Oxford; Professor DJ Murphy FRCOG, Dublin; Mr M Griffiths FRCOG, Eaton Bray; and Dr LK Penna FRCOG, London

and peer reviewed by:

Mrs K Adamson, Registered Midwife, Woodchester; Dr G Akaba, University of Abuja Teaching Hospital, Gwagwalada, Nigeria; American College of Obstetricians and Gynaecologists; Dr E Azria, French Institute of Health and Medical Research, Paris, France; Dr JFR Barrett, Sunnybrook Health Sciences Centre, Toronto, Canada; Dr A Bisits, Royal Hospital for Women, Sydney, Australia; Mrs R Blum, Winchester; Dr JF Bodle MRCOG, Sheffield; Dr G Bogner, Paracelsus Private Medical University of Salzburg, Austria; Dr M Burnett, The Society of Obstetricians and Gynaecologists of Canada, Ottowa, Ontario, Canada; Miss V Cochrane, St Mary's Hospital, London; Dr PJ Danielian FRCOG, Aberdeen; Dr J Davidson, Maidstone and Tunbridge Wells NHS Trust; Dr M de Hundt, Medical Centre Alkmaar, the Netherlands; Mrs A Diyaf MRCOG, Barnstaple; Mrs H Dresner Barnes, Sheffield Teaching Hospital; Mrs J Evans, Independent Midwife, Dorchester; Dr R Fernando, University College London; Dr SJ Fischbein, Obstetrics and Gynaecology, Los Angeles, California, USA; Mrs N Grace, Independent Midwife, Nottingham; Ms G Gyte, Cochrane Pregnancy and Childbirth Group, Liverpool; Dr HKS Hinshaw FRCOG, Sunderland; Mrs J Horner, Independent Midwife, Glastonbury; Mr B Kumar FRCOG, Wrexham; Mrs G Kumar FRCOG, Wrexham; Dr EG McGregor, Bedford; Ms E Prochaska, Founder of Birthrights, London; RCOG Women's Network; Dr A Reitter FRCOG, Frankfurt, Germany; Royal College of Anaesthetists; Professor JG Thornton FRCOG, Nottingham; Dr SG Uddin, National Center for Health Statistics, Hyattsville, Maryland, USA; Dr F Vendittelli, French College of Gynecologists and Obstetricians, Bordeaux, France; Ms S Walker, Barts Health NHS Trust, London; Dr CF Weiniger, The Hebrew University of Jerusalem, Israel.

Committee lead reviewers were: Dr M Gupta MRCOG, London and Miss P Sarkar FRCOG, Gerrards Cross.

The chairs of the Guidelines Committee were: Dr M Gupta[1] MRCOG, London; Dr P Owen[2] FRCOG, Glasgow; and Dr AJ Thomson[1] MRCOG, Paisley.

[1]co-chairs from June 2014 [2]until May 2014.

All RCOG guidance developers are asked to declare any conflicts of interest. A statement summarising any conflicts of interest for this guideline is available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg20b/

The final version is the responsibility of the Guidelines Committee of the RCOG.

The review process will commence in 2020, unless otherwise indicated.

